ArticleJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2015
Racial diversity of actionable mutations in non-small cell lung cancer.
Article in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 54 citations in OpenAlex.
- Pooled it
- A systematic review of genetic ancestry as a risk factor for incidence of non-small cell lung cancer in the US.Frontiers in genetics · 2023Pooled it
- Real World Outcomes for the Efficacy and Safety of Osimertinib in Black Patients With Nonsmall Cell Lung Cancer.Clinical lung cancer · 2026Article
- SOMATIC MUTATION PROFILES IN COLORECTAL CANCERS DIFFER BY POPULATION.medRxiv : the preprint server for health sciences · 2026Article
- Who Gets Left Out of Precision Oncology? Real-World Driver Mutation Expression Patterns and Therapeutic Eligibility in a Diverse Single-Center Early-Stage Lung Adenocarcinoma Cohort.Journal of racial and ethnic health disparities · 2026Article
- Article
- Real-World Incidence of Anaplastic Lymphoma Kinase Alterations in Hispanics with Non-Small Cell Lung Cancer at a Large Academic Institution in Los Angeles.Cancer research communications · 2025Article
- An elevated rate of whole-genome duplications in cancers from Black patients.Nature communications · 2024Article
- Cooperation between PRMT1 and PRMT6 drives lung cancer health disparities among Black/African American men.iScience · 2024Article
- Clinical outcomes of chemotherapy in cancer patients with different ethnicities.Cancer reports (Hoboken, N.J.) · 2023Review
- Surveillance of cfDNA Hot Spot Mutations in NSCLC Patients during Disease Progression.International journal of molecular sciences · 2023Article
- Disparity and Diversity in NSCLC Imaging and Genomics: Evaluation of a Mature, Multicenter Database.Cancers · 2023Article
- Sociodemographic Survival Disparities for Lung Cancer in the United States, 2000-2016.Journal of the National Cancer Institute · 2022Article
- Histologic and Genotypic Characterization of Lung Cancer in the Inuit Population of the Eastern Canadian Arctic.Current oncology (Toronto, Ont.) · 2022Article
- Racial disparities in the genetic landscape of lung cancer.Cancer health disparities · 2022Article
- Genomic landscape of lung adenocarcinomas in different races.Frontiers in oncology · 2022Article
- Racial Disparities in Treatment Patterns and Survival Among Surgically Treated Malignant Pleural Mesothelioma Patients.Journal of immigrant and minority health · 2020Article
- Whole-Exome Profiling of NSCLC Among African Americans.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2020Article
- Survival Disparities in Black Patients With EGFR-mutated Non-small-cell Lung Cancer.Clinical lung cancer · 2020Article
- Ultra-Deep Massive Parallel Sequencing of Plasma Cell-Free DNA Enables Large-Scale Profiling of Driver Mutations in Vietnamese Patients With Advanced Non-Small Cell Lung Cancer.Frontiers in oncology · 2020Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on byIn Response.2015
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
introductionLung cancer is the leading cause of cancer-related deaths in the US. The reasons for higher incidence and poorer survival rates among black compared with white lung cancer patients have not been defined. We hypothesized that differential incidence of somatic cancer gene mutations may be a contributing factor. Previous genomic studies of non-small cell lung cancer (NSCLC) have not adequately represented black patients.
methodsA matrix-assisted laser desorption/ionization and time-of-flight mass spectrometry approach was used to analyze tumor DNA for 214 coding mutations in 26 cancer genes previously identified in NSCLC. The samples included NSCLC from 335 white patients and 137 black patients. For 299 of these, normal matched DNA was available and analyzed.
resultsEpidermal growth factor receptor (EGFR) exon 19 deletions were only detected in women cases, with increased odds for black women compared with white women (odds ratio = 3.914, 95% confidence interval: 1.014-15.099, p = 0.048). Beyond race, variations in mutation frequencies were seen by histology. DDR2 alterations, previously described as somatic mutations, were identified as constitutional variants.
conclusionsThis study is among the largest comparing somatic mutations in black and white patients. The results point to the molecular diversity of NSCLC and raise new questions as to the importance of inherited alleles. Genomic tumor testing will benefit both populations, although the mutation spectrum appears to vary by sex, race, and histology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.